The Impact of Advisory Committee Votes Looks like a slam dunk to me
Study between 2008 - 2012
NOTE: MCNA was granted a priority status and is meeting with Oncology Adcom
169 Total Meetings
22 Oncology Drug review
77 assigned standard designation
77 granted priority review status
15 orphan designation
Yes vote
Standard = 45
Priority = 59
Orphan = 9
Approved by FDA
Standard = 37
Priority = 53
Orphan = 9
Specific to ODAC (Oncology Drugs Adcom)
Yes vote
Standard = 5
Priority = 15
Orphan = 2
Approved by FDA
Standard = 4
Priority = 15